Search research articles
Contact Us
Filters
Showing results (101-110 of 220) with videos related to
Page
of 22
Sort By:
Primary Care Respiratory Journal : Journal of the General Practice Airways Group
|
October 12, 2013
Management of COPD exacerbations in primary care: a clinical cohort study
Josefin Sundh, Eva Österlund Efraimsson, Christer Janson, et al.
Alimentary Pharmacology & Therapeutics
|
February 10, 2021
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Ochsner Journal
|
December 22, 2016
Osteochondral Allograft Transplantation for Femoral Trochlear Dysplasia
Dharmpal V Vansadia, James R Heltsley, Scott Montgomery, et al.
World Journal of Surgery
|
April 7, 2021
Validity of Routinely Collected Swedish Data in the International Enhanced Recovery After Surgery (ERAS) Database
Yin Xu, Ruzan Udumyan, Katja Fall, et al.
Acta Oncologica (Stockholm, Sweden)
|
July 26, 2022
Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based cohort study
Ruzan Udumyan, Edoardo Botteri, Tomas Jerlstrom, et al.
Acta Dermato-Venereologica
|
March 17, 2026
Quality of Life and Economic Burden in Swedish Adults with Atopic Dermatitis: A Cross-sectional Survey of Patientreported Outcomes
Alexandra Metsini, Linda Ryen, Scott Montgomery, et al.
Brain : a Journal of Neurology
|
March 11, 2021
Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis
Yin Xu, Kelsi A Smith, Ayako Hiyoshi, et al.
BMJ Open
|
November 1, 2013
Respiratory infections in preterm infants and subsequent asthma: a cohort study
Scott Montgomery, Shahram Bahmanyar, Ole Brus, et al.
Alimentary Pharmacology & Therapeutics
|
December 19, 2020
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Alimentary Pharmacology & Therapeutics
|
April 8, 2021
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Page
of 22
Search research articles
Search
Showing results (101-110 of 220) with videos related to
Sort By:
Page
of 22
Primary Care Respiratory Journal : Journal of the General Practice Airways Group
|
October 12, 2013
Management of COPD exacerbations in primary care: a clinical cohort study
Josefin Sundh, Eva Österlund Efraimsson, Christer Janson, et al.
Alimentary Pharmacology & Therapeutics
|
February 10, 2021
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Ochsner Journal
|
December 22, 2016
Osteochondral Allograft Transplantation for Femoral Trochlear Dysplasia
Dharmpal V Vansadia, James R Heltsley, Scott Montgomery, et al.
World Journal of Surgery
|
April 7, 2021
Validity of Routinely Collected Swedish Data in the International Enhanced Recovery After Surgery (ERAS) Database
Yin Xu, Ruzan Udumyan, Katja Fall, et al.
Acta Oncologica (Stockholm, Sweden)
|
July 26, 2022
Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based cohort study
Ruzan Udumyan, Edoardo Botteri, Tomas Jerlstrom, et al.
Acta Dermato-Venereologica
|
March 17, 2026
Quality of Life and Economic Burden in Swedish Adults with Atopic Dermatitis: A Cross-sectional Survey of Patientreported Outcomes
Alexandra Metsini, Linda Ryen, Scott Montgomery, et al.
Brain : a Journal of Neurology
|
March 11, 2021
Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis
Yin Xu, Kelsi A Smith, Ayako Hiyoshi, et al.
BMJ Open
|
November 1, 2013
Respiratory infections in preterm infants and subsequent asthma: a cohort study
Scott Montgomery, Shahram Bahmanyar, Ole Brus, et al.
Alimentary Pharmacology & Therapeutics
|
December 19, 2020
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Alimentary Pharmacology & Therapeutics
|
April 8, 2021
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Page
of 22